The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis
Open accessAbstract
BACKGROUND: A systematic review was undertaken to evaluate the efficacy of tiotropium, a long acting anticholinergic drug, on clinical events, symptom scales, pulmonary function, and adverse events in stable chronic obstructive pulmonary disease (COPD). METHODS: A systematic search was made of the Cochrane trials database, MEDLINE, EMBASE, CINAHL, and a hand search of 20 respiratory journals. Missing data were obtained from authors and the manufacturer. Randomised controlled trials of > or =12 weeks' duration comparing tiotropium with placebo, ipratropium bromide, or long acting beta2 agonists (LABA) were reviewed. Studies were pooled to yield odds ratios (OR) or weighted mean differences with 95% confidence intervals (CI). RESULTS: Nine trials (8002 patients) met the inclusion criteria. Tiotropium reduced the odds of a COPD exacerbation (OR 0.73; 95% CI 0.66 to 0.81) and related hospitalisation (OR 0.68; 95% CI 0.54 to 0.84) but not pulmonary (OR 0.50; 95% CI 0.19 to 1.29) or all-cause (OR 0.96; 95% CI 0.63 to 1.47) mortality compared with placebo and ipratropium. Reductions in exacerbations and hospitalisations compared with LABA were not statistically significant. Similar patterns were evident for quality of life and symptom scales. Tiotropium yielded greater increases in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) from baseline to 6-12 months than did placebo, ipratropium, and LABA. Decline in FEV1 over 1 year was 30 ml (95% CI 7 to 53) slower with tiotropium than with placebo and ipratropium (data were not available for LABA). Reports of dry mouth and urinary tract infections were increased with tiotropium. CONCLUSIONS: Tiotropium reduced COPD exacerbations and related hospitalisations, improved quality of life and symptoms, and may have slowed the decline in FEV1. Long term trials are warranted to evaluate the effects of tiotropium on decline in FEV1 and to clarify its role compared with LABA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035 · cited 1×
“George’s Respiratory Questionnaire [SGRQ] [8]), symptom scores (the Transitional Dyspnea Index [TDI], a multidimensional measure of breathlessness [9]), change in trough FEV1 and forced ventilatory capacity (FVC) from baseline and from steady state 8-15 days after randomisation, and adverse events (dry mouth, constipa…”
BackgroundA comparison of methods to detect publication bias in meta‐analysis
Macaskill, P., Walter, S. D., & Irwig, L. (2001) · Statistics in Medicine · doi:10.1002/sim.698 · Cited by 1,286 · cited 1×
“Publication bias was examined in funnel plots and tested with a modified Macaskill’s test.[14] Effects of tiotropium were examined across pre-defined subgroups by disease severity and concurrent LABA use.”
Method
Cited by
Wedzicha, J. A., Calverley, P. M. A., Seemungal, T. A., Hagan, G., Ansari, Z., & Stockley, R. A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-973oc · Cited by 827
O’Donnell, D. E., Aaron, S., Bourbeau, J., Hernandez, P., Marciniuk, D. D., Balter, M., Ford, G., Gervais, A., Goldstein, R., Hodder, R., et al. (2007) · Canadian Respiratory Journal · doi:10.1155/2007/830570 · Cited by 693
Leucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
Bateman, E. D., Ferguson, G. T., Barnes, N., Gallagher, N., Green, Y., Henley, M., & Banerji, D. (2013) · European Respiratory Journal · doi:10.1183/09031936.00200212 · Cited by 388
Metadata
- Authors
- Barr, R. G.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2006-10-01
- Volume
- 61
- Issue
- 10
- Pages
- 854-862
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2158530076
- Cited by
- 236
- References
- 2
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. https://app.cochat.ai/papers/10.1136/thx.2006.063271
- The paper
- Barr, R. G. (2006). Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. https://doi.org/10.1136/thx.2006.063271
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.